On Invalid Date, Novavax (NASDAQ: NVAX) reported Q4 2023 earnings per share (EPS) of -$1.47, up 35.81% year over year. Total Novavax earnings for the quarter were -$178.39 million. In the same quarter last year, Novavax's earnings per share (EPS) was -$2.29.
As of Q1 2024, Novavax's earnings has grown year over year. Novavax's earnings in the past year totalled -$545.06 million.
What is NVAX's earnings date?
Novavax's earnings date is Invalid Date. Add NVAX to your watchlist to be reminded of NVAX's next earnings announcement.
What was NVAX's revenue last quarter?
On Invalid Date, Novavax (NASDAQ: NVAX) reported Q4 2023 revenue of $291.34 million up 18.48% year over year. In the same quarter last year, Novavax's revenue was $357.40 million.
What was NVAX's revenue growth in the past year?
As of Q1 2024, Novavax's revenue has grown -50.36% year over year. This is 215.98 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Novavax's revenue in the past year totalled $983.71 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.